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a b s t r a c t
The synthesis of several diorganotin(IV) dicarboxylate compounds, including acetates and nicotinates as
well as diorganotin(IV) dichloride complexes of the ligands phen, dione and dppz were undertaken. Sev-
eral difficulties in either the syntheses or complexation reactions with the organic ligands were encoun-
tered. The diorganotin(IV) dichloride complexes of the ligands (R2SnCl2L where R = Me, n-Bu or Ph and
L = phen, dione or dppz) were tested against Escherichia coli, Staphylococcus aureus and Pseudomonas aeru-
ginosa. The dibutyltin(IV) derivatives exhibited the broadest range of activity in comparison to the
dimethyltin(IV) or diphenyltin(IV) derivatives. The addition of the nicotinate group did not promote
activity against any of the bacteria. Furthermore, only in the case of Ph2SnCl2dione was there improved
activity compared to the organic ligand itself.
 2013 Elsevier B.V. All rights reserved.
1. Introduction
The development of new therapeutic agents is paramount in to-
day’s society. The role of metal-based drugs in this regard has been
understated, with questions being asked regarding the toxicity is-
sues of such compounds. To date, the platinum-based compounds,
for example, are among the few metal-based drugs which are
available for cancer treatment [1]. However, it should be noted that
platinum-based drugs are not effective against all forms of cancer.
Therefore, there is an urgent need to develop new metal-based
drug therapies against a wide range of diseases.
The investigation of the cytotoxicity/anti-tumour activities of
organotin(IV) compounds remains an important area of research
[2–4]. The activity of organotin(IV) compounds depends upon the
number and nature of the organo group linked to the tin ion as well
as on the anionic ligand. Organotin(IV) carboxylates are being
extensively studied because of their biological activities, particu-
larly their anti-tumour and anti-cancer activities [5–11]. A signifi-
cant amount of the work carried out on these organotin(IV)
compounds was in relation to their antibacterial activity against
a wide range of both Gram-negative and Gram-positive bacteria.
The recent work of McCann and co-workers into the copper(II)
and silver(I) complexes of 1,10-phenanthroline and 1,10-phenan-
throline-5,6-dione have shown that they are active in vitro anti-
cancer agents against selected cancer cell lines [12–19]. Our
interest in the area of therapeutic agents, especially metal-based
drugs, is fuelled by the search for new effective medicines for hu-
man health, particularly in the areas of cancer therapy and anti-
microbials. To the best of our knowledge, the synthesis and biolog-
ical activity of 1,10-phenanthroline derivatives of simple organo-
tin(IV) chlorides and acetates against Escherichia coli,
Staphylococcus aureus and Pseudomonas aeruginosa has not been re-
ported. Herein, as a part of our ongoing research projects, we re-
port the synthesis, characterisation and biological activities of
some diorganotin(IV) chlorides and acetates and their 1,10-phe-
nanthroline derivatives.
2. Experimental
2.1. Methods and materials
1H and 13C NMR (d ppm; J Hz) spectra were recorded on a Bru-
ker Avance 300 MHz NMR spectrometer using either saturated
CDCl3 or d6-DMSO solutions with Me4Si reference with resolutions
of 0.18 Hz and 0.01 ppm, respectively. Infrared spectra (cm1)
were recorded as KBr discs using a Perkin Elmer System 2000 FT-
IR spectrometer. Melting point analyses were carried out using a
Stewart Scientific SMP 1 melting point apparatus and are uncor-
rected. Microanalyses were carried out at the Microanalytical Lab-
oratory of the National University of Ireland Maynooth. Standard
Schlenk techniques were used throughout. Starting materials were
commercially obtained and used without further purification. The
synthesis of dione [20,21] and dppz [22,23] have been described
previously, as has that for Me2SnCl2phen, [24] n-Bu2SnCl2phen
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[25] and Ph2SnCl2phen [26]. 1H NMR data for phen, dione and
ddpz are included for comparison purposes.
2.2. Synthesis of ligands
2.2.1. 1,10-Phenanthroline (phen)
1H NMR (300 MHz, d6-DMSO): 9.10 (2H, dd, J = 4.4, 1.8 Hz), 8.49
(2H, dd, J = 8.0, 1.8 Hz), 7.99 (2H, s), 7.77 (2H, dd, J = 8.0, 4.4 Hz); 1H
NMR (300 MHz, CDCl3): 9.17 (2H, d, J = 4.3 Hz), 8.22 (2H, d,
J = 8.0 Hz), 7.76 (2H, s), 7.60 (2H, dd, J = 8.0, 4.3 Hz); 1H NMR
(300 MHz, d6-DMSO, 70 C): 9.06 (2H, dd, J = 4.3, 1.7 Hz), 8.37
(2H, dd, J = 8.1, 1.7 Hz), 7.86 (2H, s), 7.69 (2H, dd, J = 8.1, 4.3 Hz);
13C NMR (75 MHz, d6-DMSO, 70 C): 149.8, 145.4, 136.1, 128.4,
126.5, 123.2.
2.2.2. 1,10-Phenanthroline-5,6-dione (dione) [20,21]
1H NMR (300 MHz, d6-DMSO): 8.98 (2H, dd, J = 4.7, 1.7 Hz), 8.39
(2H, dd, J = 7.8, 1.7 Hz), 7.68 (2H, dd, J = 7.8, 4.7 Hz); 1H NMR
(300 MHz, CDCl3): 9.10 (2H, dd, J = 4.7, 1.8 Hz), 8.49 (2H, dd,
J = 7.8, 1.8 Hz), 7.57 (2H, dd, J = 7.8, 4.7 Hz).
2.2.3. Dipyridophenazine (dppz) [22,23]
1H NMR (300 MHz, d6-DMSO): 9.49 (2H, dd, J = 8.1, 1.8 Hz), 9.20
(2H, dd, J = 4.4, 1.8 Hz), 8.36 (2H, dd, J = 6.5, 3.4 Hz), 8.04 (2H, dd,
J = 6.5, 3.4 Hz), 7.92 (2H, dd, J = 8.1, 4.4 Hz); 1H NMR (300 MHz,
CDCl3): 9.64 (2H, dd, J = 8.1, 1.7 Hz), 9.26 (2H, dd, J = 4.5, 1.7 Hz),
8.35 (2H, dd, J = 6.5, 3.4 Hz), 7.92 (2H, dd, J = 6.5, 3.4 Hz), 7.80
(2H, dd, J = 8.1, 4.5 Hz); 1H NMR (300 MHz, d6-DMSO, 80 C):
9.41 (2H, dd, J = 8.1, 1.7 Hz), 9.13 (2H, d, J = 4.3 Hz), 8.27 (2H, dd,
J = 6.5, 3.4 Hz), 7.98 (2H, dd, J = 6.5, 3.4 Hz), 7.85 (2H, dd, J = 8.1,
4.3 Hz). 13C NMR (75 MHz, d6-DMSO, 80 C): 152.1, 147.7, 141.6,
140.5, 132.9, 131.0, 128.9, 126.7, 124.3; 1H NMR (300 MHz, d6-
DMSO, 95 C): 9.45 (2H, dd, J = 8.1, 1.7 Hz), 9.15 (2H, br s), 8.30
(2H, dd, J = 6.5, 3.5 Hz), 7.99 (2H, dd, J = 6.5, 3.5 Hz), 7.87 (2H, dd,
J = 8.1, 4.4 Hz). 13C NMR (75 MHz, d6-DMSO, 95 C): 161.6, 151.9,
141.6, 140.4, 132.8, 130.9, 128.8, 126.7, 124.1.
2.3. Synthesis of organotin(IV) acetates
2.3.1. General synthesis of R2Sn(O2CMe)Cl, R = Me or n-Bu
The appropriate diorganotin(IV) dichloride (4.5 mmol) and ace-
tic acid (9.1 mmol) were dissolved in toluene (25 mL). Triethyl-
amine (10 mmol) was added slowly and the reaction mixture
was heated to reflux for 3 h under nitrogen. On cooling, a white so-
lid precititated, which was removed by celite filtration and the fil-
trate collected. Solvent was removed under reduced pressure to
yield the desired product as a white solid.
Me2Sn(O2CMe)Cl [27]: Yield: 0.80 g, 73%. m.p. >300 C. 1H NMR
(300 MHz, CDCl3): 1.93 (3H, s), 0.78 (3H, s, 2J(119/117Sn, 1H = 92.7/
82.2 Hz), 0.75 (3H, s, 2J(119/117Sn, 1H = 139.8/126.6 Hz).
n-Bu2Sn(O2CMe)Cl: Yield: 1.30 g, 88%. m.p. 36–39 C. IR (solid,
cm1): 2958 (s), 2928 (s), 2872 (s), 1637 (s), 1571 (s), 1428 (s),
1376 (s), 1312 (s), 1012(m), 737 (m). 1H NMR (300 MHz, CDCl3):
1.96 (3H, s), 1.64 (4H, m) 1.35 (8H, m), 0.91 (6H, m). 13C NMR
(75 MHz, CDCl3): 177.2 (C@O), 27.5 (CH2), 27.2 (CH2), 26.9 (CH2),
26.7 (CH2), 22.9(O2CCH3), 13.5 (CH3). Anal. Calc. for C10H21ClO2-
Sn1/4(C6H5CH3): C, 40.27; H, 6.81. Found: C, 39.28; H, 6.84%.
2.3.2. Synthesis of Ph2Sn(O2CMe)Cl
Diphenyltin(IV) dichloride (4.5 mmol) and acetic acid
(9.1 mmol) were dissolved in benzene (25 mL). Potassium carbon-
ate (10 mmol) was added and the reaction mixture refluxed over-
night under nitrogen. The reaction mixture was allowed to cool
and was filtered through celite. The filtrate was collected and the
solvent removed under reduced pressure.
Ph2Sn(O2CMe)Cl: Yield: 1.29 g, 79%. m.p. >300 C. IR (solid,
cm1): 3429 (m), 3044 (m), 1551 (s), 1480 (m), 1429 (s), 1076
(m), 728 (s), 696 (s), 443 (m). 1H NMR (300 MHz, CDCl3): d 7.68
(m), 7.43 (m), 2.15 (s). 13C NMR (75 MHz, CDCl3): 178.5 (C@O),
136.8 (phenyl CH), 129.9 (phenyl CH), 128.8 (phenyl CH), the qua-
ternary phenyl carbon is believed to be under of these peaks, 20.7
(O2CCH3). Anal. Calc. for C14H13ClO2Sn: C, 45.76; H, 3.57. Found: C,
45.08; H, 3.24%.
2.4. Synthesis of organotin(IV) nicotinates
2.4.1. General synthesis of R2Sn(nicotinate)2, R = Me, n-Bu or Ph
The appropriate diorganotin(IV) oxide (1.2 mmol) and nicotinic
acid (2.4 mmol) were dissolved in toluene (25 mL). The reaction
mixture was then heated to reflux for 2 h under nitrogen. On cool-
ing, the solvent was removed under reduced pressure to yield a
white solid. This was then washed with cold methanol and col-
lected by filtration to give the desired product.
Me2Sn(nicotinate)2: Yield: 0.36 g, 76%. m.p. dec. (>200 C). IR
(solid, cm1): 3422 (w), 3063 (w), 1605 (s), 1593 (s), 1554 (s),
1441 (sh), 1417 (s), 1399 (s), 1195 (w), 867 (m), 712 (m). 1H
NMR (300 MHz, d6-DMSO): 9.05 (2H, s), 8.71 (2H, d, J = 4.7 Hz),
8.24 (2H, dt, J = 7.8, 1.9 Hz), 7.78 (2H, dd, J = 7.8, 4.7 Hz), 0.94
(6H, s, 2J(119Sn, 1H = 85.0 Hz). 13C NMR (75 MHz, d6-DMSO):
170.2 (C@O), 152.4 (pyridine CH), 150.3 (pyridine CH), 136.9 (pyr-
idine CH), 128.4 (pyridine C, 1J(119Sn, 13C) = 51.8 Hz), 123.5 (pyri-
dine CH), 11.4 (CH3). Anal. Calc. for C14H14N2O4Sn: C, 42.79; H,
3.59; N, 7.13. Found: C, 42.38; H, 3.21; N, 7.32%.
n-Bu2Sn(nicotinate)2: Yield: 0.41 g, 72%. m.p. 152–158 C. IR
(solid, cm1): 3426 (w), 2955 (s), 2925 (s), 2867 (w), 1609 (s),
1592 (s), 1434 (sh), 1409 (s), 1196 (m), 863 (m), 756 (m). 1H
NMR (300 MHz, CDCl3): 9.07 (2H, s), 8.75 (2H, d, J = 4.2 Hz), 8.26
(2H, d, J = 7.8 Hz), 7.52 (2H, dd, J = 7.8, 4.2 Hz) 1.58 (8H, m), 1.30
(4H, m), 0.81 (6H, t, J = 7.3 Hz). 13C NMR (75 MHz, d6-DMSO):
170.9 (C@O), 152.6 (pyridine CH), 150.3 (pyridine CH), 136.9 (pyr-
idine CH), 127.9 (pyridine C), 123.6 (pyridine CH), 29.8 (CH2), 26.8
(CH2, 1J(119Sn, 13C) = 40.5 Hz), 25.6 (CH2), 13.5 (CH3). Anal. Calc. for
C20H26N2O4SnH2O: C, 48.51; H, 5.70; N, 5.66. Found: C, 49.11; H,
5.52; N, 5.50%.
Ph2Sn(nicotinate)2: Yield: 0.45 g, 73%. m.p. >300 C. IR (solid,
cm1): 3422 (m), 3076 (m), 1608 (s), 1592 (s), 1541 (s), 1440 (s),
1412 (s), 1195 (m), 871 (m), 695 (m). 1H NMR (300 MHz, d6-
DMSO): 9.11 (2H, s), 8.77 (2H, d, J = 4.8 Hz), 8.31 (2H, d,
J = 8.4 Hz), 7.80 (4H, d, J = 8.5 Hz), 7.52 (2H, dd, J = 8.4, 4.8 Hz),
7.34 (6H, m). 13C NMR (75 MHz, d6-DMSO): ⁄169.3 (C@O), 153.1
(pyridine CH), 150.4 (pyridine CH), ⁄148.6 (phenyl C), 137.1 (pyri-
dine CH), 134.0 (phenyl CH), 128.7 (phenyl CH), 128.1 (phenyl
CH), 127.0 (pyridine C), 123.7 (pyridine CH). Anal. Calc. for C24H18-
N2O4Sn: C, 55.74; H, 3.51; N, 5.42. Found: C, 55.91; H, 3.49; N,
5.28%.
⁄The compound is not very soluble and as a result these signals
are very weak.
2.5. Synthesis of phen derivatives of R2SnCl2 and R2Sn(nicotinate)2,
R = Me, n-Bu or Ph
The appropriate diorganotin(IV) compound (10 mmol) and
phen (10 mmol) were dissolved in ethanol (25 mL) and heated to
reflux for 3 h. With the chloride derivatives a solid precipitated
on cooling which was removed by filtration and dried, resulting
in the desired product. With the R2Sn(nicotinate)2 (R = Me, n-Bu)
derivatives, the resulting solution was cooled and the solvent
was removed under pressure to give the desired product. In the
case of the phenyl derivative, the resulting suspension was initially
filtered to remove unreacted starting materials and the filtrate was
then reduced under reduced pressure. The remaining solid was
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washed with cold EtOH and the filtrate reduced under reduced
pressure to give the desired product.
Me2SnCl2phen (1) [24,28]: White solid. Yield: 1.68 g, 92%. m.p.
dec. (>200 C). (lit 264 C [24,28]). 1H NMR (300 MHz, d6-DMSO):
9.32 (2H, dd, J = 4.6, 1.7 Hz), 8.74 (2H, dd, J = 8.1, 1.7 Hz), 8.16
(2H, s), 8.00 (2H, dd, J = 8.1, 4.6 Hz), 0.97 (6H, s, 2J(119/
117Sn,1H) = 114.5/109.5 Hz). 13C NMR (75 MHz d6-DMSO): 148.9
(phen CH) 142.4 (phen C), 138.2 (phen CH), 129.1 (phen C), 127.1
(phen CH), 124.4 (phen CH), 24.0 (CH3). 1H NMR (300 MHz, d6-
DMSO, 70 C): 9.38 (2H, dd, J = 4.6, 1.6 Hz), 8.75 (2H, dd, J = 8.1,
1.6 Hz), 8.15 (2H, s), 8.02 (2H, dd, J = 8.1, 4.6, Hz), 0.99 (6H, s,
2J(119/117Sn, 1H) = 113.1/108.0 Hz).
Me2Sn(nicotinate)2phen (2): Pink solid. Yield: 1.99 g, 77%. m.p.
212–220 C. IR (solid, cm1): 3431 (m), 3055 (w), 1645 (s), 1590
(s), 1428 (s), 1332 (s), 1027 (m), 846 (m), 756 (s). 1H NMR
(300 MHz, d6-DMSO): 9.46 (2H, d, J = 4.7 Hz), 9.15 (2H, br s), 8.73
(4H, m), 8.30 (2H, d, J = 7.7 Hz), 8.15 (2H, s), 8.00 (2H, dd, J = 8.5,
4.7 Hz), 7.50 (2H, dd J = 7.7, 4.4 Hz), 0.92 (6H, s). 13C NMR
(75 MHz, d6-DMSO): 170.3 (C@O), 152.1 (pyridine CH), 150.5 (pyr-
idine CH), 149.5 (phen CH), 142.0 (phen C), 138.4 (phen CH), 136.9
(pyridine CH), 129.1 (pyridine C), 129.0 (phen C), 127.0 (phen CH),
124.5 (phen CH), 123.4 (pyridine CH), 14.5 (CH3). Anal. Calc. for C26-
H22N4O4Sn: C, 54.48; H, 3.87; N, 9.77. Found: C, 54.62; H, 3.85; N,
9.66%.
n-Bu2SnCl2phen (3) [29]: White solid. Yield: 2.12 g, 98%. m.p.
192–195 C (lit 198–199 C [29]). 1H NMR (300 MHz, d6-DMSO):
9.44 (2H, dd, J = 4.7, 1.4 Hz), 8.90 (2H, dd, J = 8.2, 1.4 Hz), 8.27
(2H, s), 8.16 (2H, dd, J = 8.2, 4.7 Hz), 1.39 (4H, m), 1.25 (4H, m),
0.99 (4H, m), 0.58 (6H, t, J = 7.3 Hz).
n-Bu2Sn(nicotinate)2phen (4): Pink solid. Yield: 2.75 g, 93%.
m.p. 121–127 C. IR (solid, cm1): 3429 (m), 3047 (w), 2948 (s),
2925 (s), 2865 (m), 1648 (s), 1599 (s), 1588 (s), 1552 (m), 1426
(s), 1332 (s), 1143 (m), 848 (s), 424 (m). 1H NMR (300 MHz, d6-
DMSO): 9.48 (2H, d, J = 4.3), 9.17 (2H, br s), 8.77 (2H, d,
J = 7.5 Hz), 8.71 (2H, d, J = 4.8 Hz), 8.32 (2H, d, J = 7.7 Hz), 8.17,
(2H, s), 8.04 (2H, m), 7.48 (2H, dd, J = 7.7, 4.8 Hz), 1.53 (4H, m),
1.29 (4H, br s), 1.02 (4H, m), 0.52 (6H, t, J = 8.7 Hz). 13C NMR
(75 MHz, d6-DMSO): 170.3 (C@O), 152.0 (pyridine CH), 150.5 (pyr-
idine CH), 149.8 (phen CH), 142.3 (phen C), 138.5 (phen CH), 136.9
(pyridine CH), 129.3 (phen C), 129.0 (pyridine C), 127.1 (phen CH),
124.6 (phen CH), 123.4 (pyridine CH), 31.9 (CH2), 26.9 (CH2), 25.4
(CH2), 13.3 (CH2). Anal. Calc. for C32H34N4O4Sn2H2O: C, 55.43; H,
5.52; N, 8.08. Found: C, 55.08; H, 5.04; N, 7.85%.
Ph2SnCl2phen (5) [30]: White solid. Yield: 2.19 g, 93%. m.p. dec.
(>200 C). (lit 235 C with dec. [30]). 1H NMR (300 MHz, d6-DMSO):
⁄9.50 (2H, app s), #9.06 (2H, d, J = 8.3 Hz), ⁄8.74 (2H, app s), #8.54
(2H, d, J = 4.7 Hz), #8.43 (2H, br s), #8.25 (2H, d, J = 8.3 Hz), #8.18
(2H, m), ⁄8.12 (2H, br s), ⁄8.05 (2H, app br s), #7.92 (2H, d,
J = 7.1 Hz), ⁄7.72 (4H, d, J = 7.1 Hz), #7.49 (6H, m), ⁄7.17 (6H, m).
1H NMR (300 MHz, d6-DMSO, 70 C) d 9.49 (2H, app br s) 8.73
(2H, app br s), 8.08 (4H, m), 7.75 (4H, app br s), 7.17 (6H, app br
s). ⁄: trans isomer. #: cis isomer.
Ph2Sn(nicotinate)2phen (6): Peach solid. Yield: 0.35 g, 10%. m.p.
dec. (>200 C). IR (solid, cm1): 3432 (s), 3070 (w), 1709 (s), 1655
(s), 1596 (s), 1419 (s), 1324 (s), 1302 (s), 1033 (m), 748 (m). 1H
NMR (300 MHz, d6-DMSO): 9.09 (app bs, 2H), 9.03 (bs, 2H), 8.71
(app bs, 2H), 8.49 (app bs, 2H), 8.24 (app bs, 2H), 7.96 (app bs,
3H), 7.82 (d, J = 6.1 Hz, 2H), 7.78 (app bs, 2H), 7.51 (m, 2H), 7.41
(m, 6H), 7.12 (app bs, 1H). 13C NMR (75 MHz, d6-DMSO): 167.2
(C@O) 153.1 (pyridine CH), 150.5 (pyridine CH), 150.2 (phen CH),
145.5 (phenyl C), 143.4 (phen C), 137.5 (pyridine CH), 136.8 (phen
CH), 136.5 (phenyl CH), 129.3 (phenyl CH), 128.8 (phen C), 128.7
(phenyl CH), 128.3, (pyridine C), 127.1 (phen CH), 124.2 (pyridine
CH), 123.9 (phen CH). Anal Calc. for C36H26N4O4SnH2O: C, 60.44;
H, 3.95; N, 7.83. Found: C, 60.44; H, 3.74; N, 8.17%.
2.6. Synthesis of dione derivatives of R2SnCl2 and R2Sn(nicotinate)2,
R = Me, n-Bu or Ph
A similar procedure to that employed in Section 2.5 was used.
No dione complexes of the R2Sn(nicotinate)2 compounds were
formed.
Me2SnCl2dione (7): Yellow solid. Yield: 1.88 g, 97%. m.p. dec.
(>200 C). IR (solid, cm1): 3442 (s), 3071 (w), 1701 (s), 1573 (s),
1429 (s), 1301 (m), 731 (m). 1H NMR (300 MHz, d6-DMSO): 9.00
(2H, dd, J = 4.7, 1.8 Hz), 8.41 (2H, dd, J = 7.8, 1.8 Hz), 7.69 (2H, dd,
J = 7.8, 4.7 Hz), 1.03 (6H, s, 2J(119/117Sn, 1H) = 113.7/108.9 Hz). 13C
NMR (75 MHz d6-DMSO): 177.6 (C@O), 154.2 (dione CH), 152.0
(dione C), 135.8 (dione CH), 129.1 (dione C), 125.3 (dione CH),
22.9 (CH3, 1J(119/117Sn, 13C) = 1014.0/968.3 Hz). Anal. Calc. for C14-
H12Cl2N2O2SnEtOH: C, 40.38; H, 3.81; N, 5.89. Found: C, 41.24;
H, 3.01; N, 6.79%.
n-Bu2SnCl2dione (8): Yellow solid. Yield: 2.32 g, 99%. m.p. dec.
(>200 C). IR (solid, cm1): 3421 (s), 3076 (w), 2955 (m), 2862 (m),
1620 (w), 1584 (s), 1436 (m), 1376 (s), 1069 (s), 1042 (s), 720 (m).
Anal. Calc. for C20H24Cl2N2O2SnH2O: C, 45.15; H, 4.93; N, 5.27.
Found: C, 45.07; H, 4.69; N, 5.46%.
Ph2SnCl2dione (9): Yellow solid. Yield: 2.42 g, 97%. m.p. dec.
(>200 C). IR (solid, cm1): 3444 (s), 3058 (w), 1694 (m), 1574
(m), 1430 (m), 1351 (w), 727 (m), 700 (m). 1H NMR (300 MHz,
d6-DMSO): 9.00 (2H, dd, J = 4.7, 1.6 Hz), 8.40 (2H, dd, J = 7.8,
1.6 Hz), 7.90 (4H, d, J = 7.0 Hz), 7.68 (2H, dd, J = 7.8, 4.7 Hz), 7.35
(6H, m). 13C NMR (75 MHz, d6-DMSO): 177.3 (C@O), 155.1 (phenyl
C), 153.9 (dione CH), 151.6 (dione C), 136.0 (dione CH), 134.5 (Phe-
nyl CH, 2J(119Sn, 13C) = 69.8 Hz), 129.3 (dione C), 127.8 (phenyl CH),
127.3 (phenyl CH), 125.3 (dione CH). Anal. Calc. for C24H16Cl2N2O2-
Sn: C, 52.03; H, 2.91; N, 5.06. Found: C, 52.29; H, 3.34; N, 5.19%.
2.7. Synthesis of dppz derivatives of R2SnCl2 and R2Sn(nicotinate)2,
R = Me, n-Bu or Ph
A similar procedure to that employed in Section 2.5 was used.
Me2SnCl2dppz (10): Yellow solid. Yield: 2.14 g, 94%. m.p. 269–
272 C. IR (solid, cm1): 3434 (s), 3066 (w), 1632 (m), 1571 (m),
1494 (s), 1420 (s), 1359 (s), 1075 (s), 772 (s), 734 (s). 1H NMR
(300 MHz, d6-DMSO): 9.42 (2H, dd, J = 8.1, 1.6 Hz), 9.20 (2H, dd,
J = 4.4, 1.6 Hz), 8.29 (2H, dd, J = 6.5, 3.4 Hz), 8.01 (2H, dd, J = 6.5,
3.4 Hz), 7.91 (2H, dd, J = 8.1, 4.4 Hz), 1.03 (6H, s). 1H NMR
(300 MHz, d6-DMSO, 80 C): 9.46 (2H, d, J = 8.0 Hz), 9.21 (2H, app
br s), 8.30 (2H, dd, J = 6.5, 3.5 Hz), 7.99 (2H, dd, J = 6.5, 3.5 Hz),
7.91 (2H, dd, J = 8.0, 4.4 Hz), 1.08 (6H, s, 2J(119/117Sn, 1H) = 108.3/
103.8 Hz). 13C NMR (75 MHz, d6-DMSO, 80 C): 152.3 (dppz CH),
147.8 (dppz C), 142.3 (dppz C), 141.0 (dppz C), 133.8 (dppz CH),
131.6 (dppz CH), 129.6 (dppz CH), 127.6 (dppz C), 125.0 (dppz
CH), 21.4 (CH3). Anal. Calc. for C20H16Cl2N4Sn: C, 47.85; H, 3.21;
11.16. Found: C, 47.27; H, 3.04; N, 10.74%.
Me2Sn(nicotinate)2dppz (11): Yellow solid. Yield: 2.97 g, 98%.
m.p. dec. (>200 C). IR (solid, cm1): 3427 (m), 3063 (w), 1605 (s),
1592 (s), 1554 (m), 1486 (m), 1415 (s), 1400 (s), 1362 (m), 1336
(w), 1073 (w), 741 (m). 1H NMR (300 MHz, d6-DMSO): 9.55 (2H,
d, J = 7.9 Hz), 9.27 (2H, d, J = 4.7 Hz), 9.07 (2H, d, J = 1.5 Hz), 8.74
(2H, dd, J = 4.9, 1.9 Hz), 8.39 (2H, dd, J = 6.6, 3.5 Hz), 8.26 (2H, app
dt, J = 7.8, 1.9 Hz), 8.07 (2H, dd, J = 6.6, 3.5 Hz), 7.98 (2H, dd,
J = 7.9, 4.7 Hz), 7.50 (2H, dd, J = 7.8, 4.9 Hz), 0.95 (6H, s). 1H NMR
(300 MHz, d6-DMSO, 80 C): 9.47 (2H, d, J = 7.9 Hz), 9.22 (2H, app
br s), 9.07 (2H, bs), 8.70 (2H, dd, J = 4.8, 1.5 Hz), 8.29 (2H, dd,
J = 6.5, 3.4 Hz), 8.25 (2H, d, J = 7.8 Hz), 7.99 (2H, dd, J = 6.5,
3.4 Hz), 7.90 (2H, dd, J = 7.9, 4.3 Hz), 7.46 (2H, dd, J = 7.8, 4.8 Hz),
1.02 (6H, s, 2J(119/117Sn, 1H) = 101.7/97.5 Hz). 13C NMR (75 MHz,
d6-DMSO, 80 C): 168.6 (C@O), 151.8 (pyridine CH), 151.5 (dppz
CH), 149.9 (pyridine CH), 147.0 (dppz C), 141.3 (dppz C), 140.1
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(dppz C), 136.2 (pyridine CH), 132.7 (dppz CH), 130.6 (dppz CH),
128.6 (dppz CH), 128.2 (pyridine C), 126.5 (C4’), 123.9 (dppz CH),
122.8 (pyridine CH), 11.8 (CH3). Anal. Calc. for C32H24N6O4Sn: C,
56.92; H, 3.58; N, 12.45. Found: C, 56.49; H, 3.57; N, 12.53%.
n-Bu2SnCl2dppz (12): Salmon pink solid. Yield: 2.54 g, 96%.
m.p. 197–202 C. IR (solid, cm1): 3431 (s), 2954 (m), 2916 (m),
2858 (w), 1630 (m), 1493 (s), 1076 (s), 736 (s). 1H NMR
(300 MHz, CDCl3): 9.93 (2H, dd, J = 8.2, 1.5 Hz), 9.83 (2H, dd,
J = 4.9, 1.5 Hz), 8.41 (2H, dd, J = 6.6, 3.4 Hz), 8.14 (2H, dd, J = 8.2,
4.9 Hz), 8.03 (2H, dd, J = 6.6, 3.4 Hz), 1.65 (4H, m), 1.41 (4H, m),
1.07 (4H, m), 0.62 (6H, t, J = 6.9 Hz). 13C NMR (75 MHz, CDCl3):
150.5 (dppz CH), 142.9 (dppz C), 142.7 (dppz C), 139.3 (dppz C),
136.9 (dppz CH), 132.1 (dppz CH), 129.7 (dppz CH), 129.3 (dppz
C), 126.3 (dppz CH), 41.9 (CH2), 28.2 (CH2), 25.9 (CH2), 13.4 (CH3).
Anal. Calc. for C26H28Cl2N4Sn: C, 53.28; H, 4.81; N, 9.56. Found: C,
52.89; H, 5.22; N, 9.47%.
n-Bu2Sn(nicotinate)2dppz (13): Yellow solid. Yield: 3.07 g, 90%.
m.p. dec. (>200 C). IR (solid, cm1): 3425 (s), 2955 (s), 2924 (s),
2868 (m), 1627 (sh), 1606 (s), 1593 (s), 1553 (m), 1407 (s), 1361
(m), 1337 (m), 1074 (w), 740 (m). 1H NMR (300 MHz, d6-DMSO):
9.40 (2H, d, J = 7.8 Hz), 9.31 (2H, app bs), 9.11 (2H, br s), 8.73
(2H, d, J = 5.0 Hz), 8.28 (2H, d, J = 7.8 Hz), 8.23 (2H, dd, J = 6.5,
3.4 Hz), 7.98 (4H, m), 7.51 (2H, dd, J = 7.8, 5.0 Hz), 1.56 (8H, m),
1.21 (4H, m), 0.72 (6H, t, J = 7.2 Hz). 1H NMR (300 MHz, d6-DMSO,
95 C): 9.38 (2H, dd, J = 7.9, 1.7 Hz), 9.14 (2H, d, J = 3.9 Hz), 9.03
(2H, d, J = 1.7 Hz), 8.68 (2H, dd, J = 4.9, 1.7 Hz), 8.22 (4H, m), 7.94
(2H, dd, J = 6.6, 3.4 Hz), 7.84 (2H, dd, J = 7.9, 3.9 Hz), 7.46 (2H, dd,
J = 8.0, 4.9 Hz), 1.66 (4H, m), 1.49 (4H, m), 1.30 (4H, m), 0.80 (6H,
t, J = 7.3 Hz). 13C NMR (75 MHz, d6-DMSO, 95 C): 168.4 (C@O),
152.2 (pyridine CH), 151.9 (dppz CH), 150.0 (pyridine CH), 147.3
(dppz C), 141.6 (dppz C), 140.3 (dppz C), 136.5 (pyridine CH),
132.9 (dppz CH), 130.8 (dppz CH), 128.8 (dppz CH), 128.3 (pyridine
C), 126.7 (dppz C), 124.2 (dppz CH), 123.2 (pyridine CH), 26.4 (CH2),
25.6 (CH2), 12.9 (CH3). Anal. Calc. for C38H36N6O4Sn: C, 60.10; H,
4.78; N, 11.07. Found: C, 60.91; H, 4.90; N, 10.40%.
Ph2SnCl2dppz (14): Light yellow solid. Yield: 2.76 g, 98%. m.p.
272–282 C. IR (solid, cm1): 3443 (s), 3067 (m), 1627 (m), 1574
(m), 1494 (s), 1420 (s), 1361 (s), 1078 (s), 735 (s). 1H NMR
(300 MHz, d6-DMSO): 9.44 (2H, dd, J = 8.1, 1.7 Hz), 9.26 (2H, app
br s), 8.28 (2H, dd, J = 6.5, 3.4 Hz), 8.00 (2H, dd, J = 6.5, 3.4 Hz),
7.95 (2H, dd, J = 8.1, 4.6 Hz), 7.89 (4H, d, J = 6.7 Hz), 7.29 (6H, m).
13C NMR (75 MHz, d6-DMSO): ⁄155.1 (phenyl C), 151.9 (dppz CH),
⁄146.9 (dppz C), 141.6 (dppz C), 140.4 (dppz C), 134.5 (phenyl
CH), 133.5 (dppz CH), 131.3 (dppz CH), 129.1 (dppz CH), 127.7
(phenyl CH), 127.3 (phenyl CH), 127.1 (dppz C), 124.8 (dppz CH).
Anal. Calc. for C30H20Cl2N4Sn: C, 57.55; H, 3.22; N, 8.95. Found: C,
57.09; H, 3.23; N, 9.22%.
⁄The compound is not very soluble and as a result these signals
are very weak.
2.8. In vitro antimicrobial screening
2.8.1. Materials and methods
Nutrient Broth was obtained from Oxoid, England and made up
according to the manufacturer’s instructions (13 g in 1 L deionised
water). OD600nm values were determined using a spectrophotome-
ter (Biophotometer, Eppendorf). Optical density was read using a
microplate reader (Bio-Tek. Synergy HT Spectrophotometer). S.
aureus (a clinical isolate from a urinary tract infection, St. James
Hospital, Dublin), E. coli (a clinical isolate from a gastro-intestinal
tract infection, St. James Hospital, Dublin) and P. aeruginosa (Amer-
ican Type Culture Collection (ATCC) 10145) were used in this
study. All bacteria were grown on nutrient broth agar plates at
37 C and maintained at 4 C for short term storage. Cultures were
routinely sub-cultured every 4–6 weeks. All assays were run in
triplicate.
2.8.2. In vitro bacterial susceptibility testing
Fresh solutions (200 lg/mL) of complexes were prepared with
distilled water and DMSO (less than 1%) immediately prior to test-
ing. Complexes with low solubility were tested as fine suspensions.
Bacteria cultures were grown in nutrient broth at 37 C and
200 rpm overnight. The cells were diluted to give an OD600 = 0.1.
Nutrient broth (100 lL) was added to each well of a 96-well
flat-bottomed microtitre plate. An additional 100 lL was added
to columns 1 and 2 of the plate. Serial dilutions (1:1) of the test
complex were made from column 4–12 giving a test concentration
range of 100–0.39 lg/mL. 100 lL of the desired bacteria cell sus-
pension to be tested was added to columns 3–12. Column 3 served
as the negative control.
The plate was incubated for 24 h at 37 C. The optical density
was read at kmax 540 nm and growth was then quantified as a per-
centage of the control. The minimum inhibitory concentration
(MIC) values were then determined. The MIC80 and MIC50 (Mini-
mum Inhibitory Concentration) of any given compound was taken
to signify the concentration of compound that would inhibit the
growth of that microorganism by 80% or 50%, respectively.
3. Results and discussion
3.1. Synthesis of ligands
The 1,10-phenanthroline derivatives were chosen for two rea-
sons: firstly, due to their ease of synthesis (see Scheme 1) and sec-
ondly, steric and electronic effects are varied between these
ligands. 1,10-Phenanthroline (phen) was readily converted to
1,10-phenanthroline-5,6-dione (dione) which can be furthered re-
acted to give dipyridophenazine (dppz) [22,23]. The simplicity of
all the 1H NMR spectra of the 1,10-phenanthroline derivatives is
due to the plane of symmetry in the molecules. The signal for H-
5 at 7.99 ppm in phen disappeared in both the 1H NMR spectra
of dione and dppz. Two new signals appeared in the spectrum of
dppz due to the H-5 and H-6 protons of the extra aromatic ring.
The doublet for H-2 in the 1H NMR spectra of phen, dione and dppz
occurred at 9.10, 8.98 and 9.49 ppm respectively.
3.2. Synthesis of organotin compounds
The diorganotin(IV) chlorides were obtained commercially and
used without further purification. The organotin(IV) monoacetate
compounds (R2Sn(O2Me)Cl, R = Me, n-Bu or Ph) were synthesised
from the reaction between the corresponding organotin(IV) dichlo-
ride with acetic acid in toluene with triethylamine as base (see
Scheme 2). Their molecular structure has been elucidated by ele-
mental analyses, 1H and 13C NMR and IR spectroscopies. Elemental
analyses confirmed the presence of a single Cl in each molecule.
The 1H NMR spectra of the three organotin(IV) monoacetate com-
pounds showed a distinct singlet for the acetate signal at 1.93, 1.95
and 2.15 ppm for Me2Sn(O2Me)Cl, n-Bu2Sn(O2Me)Cl and Ph2Sn(O2-
Me)Cl, respectively, corresponding to the three protons of the ace-
tate group in all cases. In the 1H NMR spectrum of Me2Sn(O2Me)Cl,
the 2J(119/117Sn,1H) coupling constant of 139.8/126.6 Hz indicates
six coordination in solution [31–33]. The IR spectra of the three
organotin(IV) monoacetate compounds all contained a strong
absorption at ca 1700 cm1 corresponding to the m(C@O) of the
carboxyl group. The Dm difference between masym(COO) and msym(-
COO) is important to find out the binding mode of the acetate
moiety about the Sn atom. According to the literature, Dm values
greater than 250 cm1 indicates a monodentate binding mode
while a value less than 250 cm1 shows a bidentate binding mode
of the acetate moiety with the Sn atom. Furthermore, a Dm value
between 150 and 250 cm1 indicates a bridging behaviour
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[31,34–39]. In the present study, the Dm in the range 160–
210 cm1 suggests that compounds Me2Sn(O2Me)Cl, n-Bu2Sn(O2-
Me)Cl and Ph2Sn(O2Me)Cl exhibit a bridging behaviour in the solid
state. The crystal structure of Me2Sn(O2Me)Cl has been reported
[27] and consists of Me2ClSn units bridged by acetate ligands giv-
ing rise to polymeric chains. The Sn atom is in a distorted trigonal
bipyramidal environment consisting of two axial O atoms with the
equatorial positions occupied by the methyl groups and the chlo-
rine atom.
The synthesis of the diorganotin dinicotinate compounds was
carried out as shown in Scheme 3. In all cases, the starting organotin
compoundwas the corresponding diorganotin oxide. In the 1HNMR
spectra of the diorganotin dinicotinate compounds, the absence of
the carboxylic acid proton signal at 13.44 ppm was taken to indi-
cate that the reactions had occurred. In the 1H NMR spectrum of
Me2Sn(nicotinate)2, the 2J(119Sn, 1H) coupling constant of 85.0 Hz
indicates six coordination in solution [32,33]. Furthermore, Lock-
hart et al. have shown that the coordination geometry about the
tin atom results in trans organo groups [40]. The IR spectra of the
diorganotin dinicotinate compounds all contained a strong absorp-
tion at ca 1600 cm1 corresponding to the m(C@O) of the carboxyl
group. Furthermore, the shift in the C@O band in the IR spectra of
the three diorganotin dinicotinate compounds from 1713 cm1 in
nicotinic acid to 1605, 1609 and 1608 cm1 was also proof of the
formation of the Me2Sn(nicotinate)2, n-Bu2Sn(nicotinate)2 and
Ph2Sn(nicotinate)2 products. According to the literature, a Dm dif-
ference between masym(COO) and msym(COO) of a value less than
150 cm1 is indictive of a chelate structure [31,34–39]. The values
obtained for the three diorganotin dinicotinate compounds were
less than 150 cm1, implying a chelate structure occurs in the solid
state, as shown in Scheme 3. Elemental analysis confirmed, in all
cases, the formation of the diorganotin dinicotinate compounds.
3.3. Complexation reactions
The synthesis of the organotin complexes of the 1,10-phenan-
throline derivatives generally involved the heating of the two
materials in ethanol at reflux temperature for 3 h. After cooling
the solution, solids precipitated in most cases. However, no reac-
tion was observed between any of the organotin(IV) monoacetate
compounds (R2Sn(O2Me)Cl, R = Me, n-Bu or Ph) and any of the
1,10-phenanthroline derivatives. This is probably as a result of
the organotin monoacetate compounds have achieved a six coordi-
nate geometry in solution. If the 1,10-phenanthroline derivatives
are to bind to the organotin compounds, then they must initially
disrupt this bridging process, resulting in a seven-coordinate tin
species, as outlined in Fig. 1. However, because the 1,10-phenan-
throline derivatives are not only large molecules but also very rigid
and planar in nature, we believe that they are unable to fit into the
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Scheme 1. Reaction conditions: (i) HNO3, H2SO4, KBr,D, 3 h; (ii) 1,2-diaminobenzene, methanol, 50 C for 2 h, then reflux for 12 h. Numbering system for 1H NMR also shown.
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Scheme 2. Reaction conditions: (i) acetic acid, triethylamine, toluene, D, 3 h for R = Me, n-Bu, and acetic acid, potassium carbonate, benzene, D, 12 h for R = Ph.
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Scheme 3. Reaction conditions: (i) nicotinic acid, toluene, D, 8 h; R = Me, n-Bu or Ph.
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geometry constraint required by the proposed seven coordination
on steric grounds.
Fourteen organotin(IV) complexes were prepared by the one-
step reaction of the organotin(IV) dichlorides or the organotin(IV)
dinicotinates with the corresponding 1,10-phenanthroline deriva-
tives. In all cases, clear solutions were obtained, from which cream
or pale yellow powders resulted on removal of some of the solvent.
Elemental analyses indicated that the solids were 1:1 complexes
between the organotin(IV) compounds and the 1,10-phenathroline
derivatives. In some cases, some solvent molecules of crystallisa-
tion were also included. The 1H NMR spectra of the eight R2SnCl2
compounds (R = Me, n-Bu or Ph) were obtained using d6-DMSO
as solvent, except for the case of n-Bu2SnCl2dione which was
insoluble and for the case of n-Bu2SnCl2dppz which was soluble
in CDCl3. All attempts to obtain 119Sn NMR spectra of the com-
plexes obtained during this study always resulted in broad signals
being obserrved, no matter what solvent was chosen or the num-
ber of scans used – this is despite the fact that clean 1H and 13C
spectra were readily obtained on the same samples.
The X-ray structures of Me2SnCl2phen (1) [24], n-Bu2SnCl2-
phen (3) [41] and Ph2SnCl2phen (5) [26] are known and show that
the Sn atom sits in an octahedral geometry with the organo groups
sitting in the axial positions. It is expected that the other 1,10-phe-
nanthroline ligands will coordinate to Sn in the same manner (see
Fig. 2). In the case of the phen ligand in this study, coordination of
the ligand to the organotin(IV) dichloride is obvious with large
shifts in the 1H NMR signals associated with the phen ligand. 1H
NMR shifts are also observed in the cases of the dppz ligands,
although these are much smaller in nature. The 2J(119/117Sn,1H) val-
ues of reported phen and dppz complexes of Me2SnCl2 are similar
to those observed in this study, suggesting a trans-orientation of
the organo groups [26,42].
In the case of the dione ligand, the signals for the complexes are
very similar to those of the starting dione ligand. It is strange that
this should happen as the ligands are all 1,10-phenanthroline
derivatives and therefore should chelate through the two nitrogen
atoms. If the size of the ligand was an issue, then it would be ex-
pected that the dppz ligand would cause problems and not the
dione ligand. However, the size of the ligand cannot really be an is-
sue, as the binding site is remote from the rest of the molecule and
is consistent amongst the series. A second explanation for the lack
of interaction in all the cases of the dione ligand may be down to
the fact that the dione ligand contains two potential binding sites,
one through the two nitrogen atoms and the second through the
two oxygen atoms (see Scheme 1). This dual binding of the ligand
could be the reason for the lack of solubility of the n-Bu2SnCl2-
dione (8) complex as a result of the possible polymeric nature of
the 1:1 complex formed, through the formation of 8-coordinate
tin atoms as a result of coordination to two organic groups, two
chlorine atoms and the two nitrogen atoms and the two oxygen
atoms of the ligand. Alternatively, it may just be that the dione li-
gand is a weakly binding ligand and only associates weakly in solu-
tion. When the solvent is removed at the end of the reaction, what
we are left with is simply a mixture of the two starting materials
rather than the formation of a new complex. The elemental analy-
ses of the dione complexes all suggest the presence of a 1:1 com-
plex but this could equally be a simple 1:1 mixture of the
starting materials, which is why the 1H NMR spectra of these
‘‘complexes’’ show no shift in the proton signals of the dione
ligand.
The 1H NMR spectra of the five R2Sn(nicotinate)2 compounds
(R = Me, n-Bu or Ph) were also obtained using d6-DMSO as solvent.
Unlike Me2SnCl2phen (1) [24], n-Bu2SnCl2phen (3) [41] and Ph2-
SnCl2phen (1) [26] where the X-ray structures are known, there
is no X-ray structural data available for R2Sn(nicotinate)2phen
(R = Me, n-Bu or Ph) or any other 1,10-phenanthroline derivative.
However, from the 1H NMR data given in the experimental section,
it is obvious that the 1,10-phenanthroline derivatives are binding
to the tin atom as can be clearly seen from signal shifts. The IR
spectra of the organotin(IV) dinicotinate complexes of the 1,10-
phenanthroline derivatives all contained a strong absorption at
ca 1600 cm1 corresponding to the m(C@O) of the carboxyl group.
The Dm[masym(COO)  msym(COO)] values for these complexes of
>200 cm1 suggested a monodentate chelating (bridging through
one oxygen atom) coordination mode of the carboxyl group in
these complexes [38,43]. This imples that the Sn(IV) centre in these
complexes is coordinated by two C atoms from the two organic
groups, two N atoms from the 1,10-phenanthroline derivative
and two O atoms from separate nicotinate groups, forming an octa-
hedral geometry about the Sn atom (see Fig. 3).
3.4. Antimicrobial activity
In order to study the bioactivity of all these organotin(IV) com-
plexes, the starting materials and the organotin(IV) complexes
were screened for their ability to inhibit the growth of the Gram-
negative bacteria E. coli and P. aeruginosa and the Gram-positive
bacterium S. aureus. The minimum inhibitory concentration
(MIC) is the concentration of a complex (expressed as either a
lM solution or a lg/mL solution) required to totally inhibit the
growth of the microorganism at 37 C. The MIC80 (Minimum Inhib-
itory Concentration) of any given compound was taken to signify
the concentration of compound that would inhibit the growth of
N
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O
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N
Sn
R
R
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Fig. 1. Proposed seven coordinate organotin structure, where N\N is the 1,10-
phenanthroline derivative, R = Me, n-Bu or Ph and R0 = pyridine.
NCl
Cl N
Sn
R
R
Fig. 2. Expected structure of 1:1 complex of organotin(IV) dichloride and 1,10-
phenathroline derivatives, where R = Me, n-Bu or Ph; N-N = 1,10-phenathroline
derivative.
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Fig. 3. Expected structure of 1:1 complex of organotin(IV) dinicotinate and 1,10-
phenathroline derivatives, where R = Me, n-Bu or Ph; N-N = 1,10-phenathroline
derivative; R0CO2 = nicotinate group.
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that microorganism by 80%. The results are summarised in Tables 1
and 2. Compounds, other than starting materials, that required
more than a lM solution of the complex to show activity against
all the bacteria are not included in the tables.
The only reagent to show good broad spectrum activity against
all three bacteria was the dione ligand. This ligand has been previ-
ously shown by McCann and co-workers to be very active against
several microbes, as well as the yeast Candida Albicans [12,15,16].
Furthermore, when they made silver(I) complexes with the dione
ligand, they found that the activity against all the bacteria was
increased.
Of the active compounds listed in Table 2, phen, Me2SnCl2phen
(1) and Ph2SnCl2dppz (14) were inactive against E. coli and Me2-
SnCl2, Ph2SnCl2, Me2SnO, Me2SnCl2phen (1) and Ph2Sn(nicotin-
ate)2 were inactive against S. aureus. The majority of complexes
synthesised exhibited little or no activity against P. aeruginosa.
However, of the active compounds, only Me2SnCl2dione (7) and
Ph2SnCl2dione (9) exhibited good activity against P. aeruginosa
with an MIC50 range of 22–29 and 23–34 lM, respectively. In both
cases, the values were slightly greater than for the dione ligand on
it’s own, so it could be concluded that the complex was breaking
up in solution before affecting the activity. However, if this was
the case that the dione complexes were breaking up before enter-
ing the cell, then the value for n-Bu2SnCl2dione (8) should also be
very similar, which is not the case. P. aeruginosa produces a thick
capsule which retards the entry of antibiotics [44]. It is possible
that it is having the same action here and preventing the entry of
the organotin complexes.
Most complexes demonstrated good to moderate activity
against both E. coli and S. aureus. S. aureus is Gram-positive and
the complexes may be directly interacting with the cell wall and
disrupting its function. E. coli is a Gram-negative bacterium sur-
rounded by a lipid bi-layer and it is this bi-layer which may be eas-
ily disrupted by the organotin(IV) complexes. Graphs 1–4 show the
activity profiles for both the phen and dione families of compounds
against both E. coli and S. aureus.
If we consider the cases of n-Bu2SnCl2phen (3) and Ph2SnCl2-
dione (9) and their respective activities against S. aureus, as
shown in Graphs 1 and 3, there could be a synergistic effect
occurring in each of these cases. The organotin compound n-Bu2-
SnCl2 is clearly active against S. aureus reaching a maximum at
25 lg/mL while the organic ligand phen has poor activity. The
Table 1
Antimicrobial activities as MIC80 range (lM and lg/mL).a
Compound E. coli P. aeruginosa S. aureus
lM lg/mL lM lg/mL lM lg/mL
Vancomycin hydrochloride 2–3 3–5 >67 >100 3–4 5–6
Dione 30–45 6–9 22–30 5–6 45–60 9–12
Me2SnCl2 >455 >100 341–455 75–100 >455 >100
n-Bu2SnCl2 41–62 13–19 >329 >100 41–62 13–19
Ph2SnCl2 218–291 75–100 >291 >100 >291 >100
n-Bu2SnCl(OAc) 114–152 37–50 >305 >100 114–152 37–50
Ph2SnCl(OAc) 136–204 50–75 >272 >100 68–102 25–37
n-Bu2SnCl2phen (3) 77–103 37–50 155–207 75–100 39–52 19–25
Me2SnCl2dione (7) >233 >100 44–59 19–25 44–58 19–25
n-Bu2SnCl2dione (8) 36–49 19–25 >195 >100 146–195 75–100
Ph2SnCl2dione (9) >181 >100 34–45 19–25 17–23 9–12
n-Bu2SnCl2dppz (12) 64–85 37–50 >171 >100 32–43 19–25
n-Bu2Sn(nicotinate)2 105–157 50–75 >209 >100 78–105 37–50
n-Bu2Sn(nicotinate)2phen (4) 114–152 75–100 >152 >100 114–152 75–100
n-Bu2Sn(nicotinate)2dppz (13) 99–132 75–100 >132 >100 >132 >100
a Values are mean of three experiments.
Table 2
Antimicrobial activities as MIC50 range (lM and lg/mL).a
Compound E. coli P. aeruginosa S. aureus
lM lg/mL lM lg/mL lM lg/mL
Vancomycin hydrochloride 1–2 2–3 >67 >100 1–2 2–3
Phen >555 >100 416–555 75–100 278–416 50–75
Dione 15–22 3–5 15–22 3–5 30–45 6–9
Me2SnCl2 341–455 75–100 341–455 75–100 >455 >100
n-Bu2SnCl2 15–21 5–6 165–247 50–75 21–31 6–9
Ph2SnCl2 55–73 19–25 >291 >100 >291 >100
Me2SnO 452–603 75–100 452–603 75–100 >603 >100
n-Bu2SnCl(OAc) 29–38 9–12 >305 >100 37–57 12–19
Ph2SnCl(OAc) 26–34 9–12 >272 >100 17–26 6–9
Me2SnCl2phen (1) >250 >100 125–188 50–75 >250 >100
n-Bu2SnCl2phen (3) 26–39 12–19 103–155 50–75 26–39 12–19
Me2SnCl2dione (7) 44–58 19–25 22–29 9–12 29–44 12–19
n-Bu2SnCl2dione (8) 18–24 9–12 146–195 75–100 49–73 25–38
Ph2SnCl2dione (9) 23–34 12–19 23–34 12–19 6–9 3–5
n-Bu2SnCl2dppz (12) 16–21 9–12 >171 >100 21–32 12–19
Ph2SnCl2dppz (14) >160 >100 80–120 50–75 60–80 37–50
n-Bu2Sn(nicotinate)2 39–52 19–25 >209 >100 26–39 12–19
Ph2Sn(nicotinate)2 72–97 37–50 >193 >100 >193 >100
n-Bu2Sn(nicotinate)2phen (4) 57–76 37–50 >152 >100 76–114 50–75
n-Bu2Sn(nicotinate)2dppz (13) 33–49 25–37 >132 >100 99–132 75–100
a Values are mean of three experiments.
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complex n-Bu2SnCl2phen (3) is between both, as it reaches the
same level of activity as n-Bu2SnCl2 at a concentration of 25 lg/
mL. In the case of Ph2SnCl2dione (9), it is a similar story. In this
case, however, the dione ligand shows a complete inhibition at
12.5 lg/mL. The Ph2SnCl2dione (9) complex has more activity
than dione at low concentrations, but never reaches complete
inhibition and seems to achieve its maximum actitivy at 80%
inhibition at 12.5 lg/mL.
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Graph 1. Activity profile for phen compounds vs. S. aureus.
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Graph 2. Activity profile for phen compounds vs. E. coli.
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Graph 3. Activity profile for dione compounds vs. S. aureus.
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In the cases of the nicotinate compounds, either as the simple
diorganotin compound or as the complex, very little activity was
observed against any of the three bacteria except in the case of
n-Bu2Sn(nicotinate)2 which exhibited reasonable activity against
S. aureus.
4. Conclusions
The synthesis of diorganotin(IV) dichloride complexes of the li-
gands phen, dione and dppz were undertaken and characterised by
CHN analyses and 1H NMR spectroscopy. We also synthesised sev-
eral diorganotin(IV) dicarboxylate compounds, including acetates
and nicotinates. However, we encountered several difficulties in
these syntheses and furthermore, complexation reactions with
the organic ligands rarely occurred. This is probably due to the dif-
ficulty in breaking the intermolecular interactions involved in dior-
ganotin(IV) dicarboxylate compounds.
Overall, the organotin(IV) compounds tested here demon-
strated greatest activity against E. coli and S. aureus and were al-
most inactive against P. aeruginosa. The dibutyltin(IV) derivatives
exhibited the broadest range of activity in comparison to the
dimethyltin(IV) or diphenyltin(IV) derivatives. The addition of
either the nicotinate group did not promote activity against any
of the bacteria. Furthermore, only in the case of Ph2SnCl2dione
(9) was there improved activity compared to the organic ligand
itself.
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Graph 4. Activity profile for dione compounds vs. E. coli.
284 N. Dolan et al. / Inorganica Chimica Acta 409 (2014) 276–284
